Verfügbarkeit: Das Blaue Buch

Das Blaue Buch: Chemotherapie-Manual Hämatologie und internistische Onkologie

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Engelhardt, Monika 1966- (VerfasserIn), Berger, Dietmar Paul (VerfasserIn), Mertelsmann, Roland 1944- (VerfasserIn)
Format:	Medienkombination Buch
Sprache:	German
Veröffentlicht:	Berlin [u.a.] Springer 2010
Ausgabe:	3. Aufl.
Schlagworte:	Krebs > Medizin Hämatologie Onkologie Cytostatikum Chemotherapie
Online-Zugang:	Inhaltsverzeichnis Klappentext
Beschreibung:	XXI, 208 S. Ill., graph. Darst. 1 CD-ROM (12 cm)
ISBN:	9783642052941 3642052940

Internformat

MARC


LEADER	00000nom a2200000 c 4500
001	BV036044484
003	DE-604
005	20100312
008	100222s2010 gw \|\|\| 0\| bnger d
015			\|a 09,N51,1332 \|2 dnb
016	7		\|a 998588954 \|2 DE-101
020			\|a 9783642052941 \|c Book with CDROM. : EUR 4.95, sfr 7.50 (freier Pr.) \|9 978-3-642-05294-1
020			\|a 3642052940 \|9 3-642-05294-0
024	3		\|a 9783642052941
028	5	2	\|a 12775231
035			\|a (OCoLC)633726973
035			\|a (DE-599)DNB998588954
040			\|a DE-604 \|b ger \|e rakddb
041	0		\|a ger
044			\|a gw \|c XA-DE-BE
049			\|a DE-20
082	0		\|a 616.994061 \|2 22/ger
084			\|a XH 3209 \|0 (DE-625)152888:12915 \|2 rvk
084			\|a 610 \|2 sdnb
100	1		\|a Engelhardt, Monika \|d 1966- \|e Verfasser \|0 (DE-588)113263538 \|4 aut
245	1	0	\|a Das Blaue Buch \|b Chemotherapie-Manual Hämatologie und internistische Onkologie \|c Monika Engelhardt ; Dietmar Berger ; Roland Mertelsmann
250			\|a 3. Aufl.
264		1	\|a Berlin [u.a.] \|b Springer \|c 2010
300			\|a XXI, 208 S. \|b Ill., graph. Darst. \|e 1 CD-ROM (12 cm)
650	0	7	\|a Krebs \|g Medizin \|0 (DE-588)4073781-0 \|2 gnd \|9 rswk-swf
650	0	7	\|a Hämatologie \|0 (DE-588)4022796-0 \|2 gnd \|9 rswk-swf
650	0	7	\|a Onkologie \|0 (DE-588)4075658-0 \|2 gnd \|9 rswk-swf
650	0	7	\|a Cytostatikum \|0 (DE-588)4068347-3 \|2 gnd \|9 rswk-swf
650	0	7	\|a Chemotherapie \|0 (DE-588)4127083-6 \|2 gnd \|9 rswk-swf
689	0	0	\|a Onkologie \|0 (DE-588)4075658-0 \|D s
689	0	1	\|a Hämatologie \|0 (DE-588)4022796-0 \|D s
689	0	2	\|a Chemotherapie \|0 (DE-588)4127083-6 \|D s
689	0	3	\|a Cytostatikum \|0 (DE-588)4068347-3 \|D s
689	0		\|8 1\p \|5 DE-604
689	1	0	\|a Onkologie \|0 (DE-588)4075658-0 \|D s
689	1	1	\|a Hämatologie \|0 (DE-588)4022796-0 \|D s
689	1	2	\|a Chemotherapie \|0 (DE-588)4127083-6 \|D s
689	1	3	\|a Krebs \|g Medizin \|0 (DE-588)4073781-0 \|D s
689	1		\|8 2\p \|5 DE-604
700	1		\|a Berger, Dietmar Paul \|e Verfasser \|0 (DE-588)111674808 \|4 aut
700	1		\|a Mertelsmann, Roland \|d 1944- \|e Verfasser \|0 (DE-588)122802187 \|4 aut
856	4	2	\|m Digitalisierung UB Regensburg \|q application/pdf \|u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018936279&sequence=000005&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA \|3 Inhaltsverzeichnis
856	4	2	\|m Digitalisierung UB Regensburg \|q application/pdf \|u http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018936279&sequence=000006&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA \|3 Klappentext
999			\|a oai:aleph.bib-bvb.de:BVB01-018936279
883	1		\|8 1\p \|a cgwrk \|d 20201028 \|q DE-101 \|u https://d-nb.info/provenance/plan#cgwrk
883	1		\|8 2\p \|a cgwrk \|d 20201028 \|q DE-101 \|u https://d-nb.info/provenance/plan#cgwrk

Datensatz im Suchindex

_version_	1804141078101622784
adam_text	Über 300 standardisierte, detaillierte und aktuelle Chemotherapieprotokolle »Das Blaue Buch« in der S.Auflage - bewährt, fundiert und therapieorientiert Das Nachschlagewerk für behandelnde Ärzte, Pflegende, Apotheker bietet eine rasche Übersicht über sichere und effektive Chemotherapieoptionen. <=> Auf dem neuesten Stand gesicherter medizinischer Erkenntnisse = Umfassend ausgearbeitet <=> Bewährt im der täglichen Praxis --- Arbeitshilfe und Informationsquelle für Klinken, Praxen und andere Institutionen Auf einen Blick finden Sie Detailinformationen zur Chemotherapie =-■ Begleitmedikatton <=> Supportive Therapie <=> Nebenwirkungen = Kontrollen c=> Notfallsitaationen <=· Hilfe zur Vermeidung von Applikationsfehlern Plus CD-ROM Nachschlagen und Ausdrucken -- Individualisierte Patientenkurvenblätter für den täglichen Gebrauch --- Standardisierte vorgehensweisen -- Clinica! Pathways -- Wichtige Interneîadressen --- Aufklärungen und Einverständniserklärungen, zum Teil auch trt englischer Sprache -- Informationsmaterial für interessierte Patienten ■-= Patiertteini-Therapiebegleiter Inhaltsverzeichnis IX Vorwort der 3. Auflage............................ V Vorwort der 1. Auflage.......................... VII Autorenverzeichnis .............................XIII Abkürzungsverzeichnis ......................... XV Einleitung.....................................XVII Teil 1 Hämatologische Neoplasien 1 Akute Leukämien 1.1 ALL GMALL B-ALL/ NHL 2002..........................4 GMALL 07/03 ....................................9 GMALL 07/ 2003 + Rituximab ....................15 1.2 AML AML99..........................................21 AML SG 07-04-Studie ............................25 S-HAM ..........................................28 Ida/ Ara 3+7.....................................29 Ida/ Ara 3+4.....................................29 MICE ............................................ ЗО mini-ICE ......................................... ЗО Azacytidine .....................................34 LD-AraC.........................................31 2 NIDS Azacytidine (75mg)..............................34 Azacytidine (50mg)..............................34 ATG/ CSA/ Decortin ..............................35 3 MPS 3.1 OMF Thalidomid/Prednison ...........................38 3.2 CML GEIST-Studie ....................................38 4 Hodgkin-Lymphome Hodgkin-Studien.................................42 HD-13-Studie..................................42 HD-14-Studie..................................43 ABVD ...........................................44 BEACOPP-Il-Basis ................................44 BEACOPP-II-gesteigert ...........................45 Vinblastin .......................................45 5 Non-Hodgkin-Lymphome 5.1 NHL-Studien GMALL 2002-Studie ............................4 Mantelzelllymphomstudie.....................55 Münchner Lymphomstudie ....................58 Unfolder-Studie...............................58 Flyer-Studie...................................60 5.2 Indolente NHL Vorphase........................................48 Chlorambucil/ Prednison (»Knospe«)..............48 COP .............................................49 Fludarabin/ Cyclophosphamid (MD Anderson) ___49 Fludarabin/ Cyclophosphamid/ Rituximab (FCR).. .50 Rituximab.......................................50 Rituximab/ Bendamustin.........................51 Fludarabin ......................................51 Trofosfamid .....................................52 Bendamustin....................................52 Alemtuzumab ...................................53 Pentostatin......................................53 Rituxirnab^-CDA................................54 2-CDA...........................................54 Zevalin/ Rituximab...............................63 PEP-C ...........................................69 5.3 Aggressive NHL R-CHOP .........................................64 CHOP ...........................................64 R-CHOP-M......................................65 CHOP-14........................................65 CHOP gesplittet .................................66 R-DHAP .........................................66 DHAP ...........................................67 R-ICE............................................63 VACOP-B ........................................67 5.4 ZNS-NHL HD-MTX/ HD-AraC-Thiotepa/ R-HD-BCNU- Thiotepa ........................................69 R-MCP/ R-MPL...................................70 5.5 Multiples Myelom/ Amyloidose DSMM XI - Studie (IEV).......................181 DSMM XI - Studie (IEV >60 Jahre).............182 DSMM XI - Studie (ATG/ Flu/ Mel)............. 198 DSMM XI - Studie (HD Melphalan)............192 DSMM Xla - Studie ...........................72 DSMMXII - Studie ............................73 Melphalan/ Prednison/Thalidomid ...............78 Melphalan/ Prednison/ Bortezomib...............78 Melphalan/ Prednison/ Lenalidomid..............76 Bortezomib .....................................82 Bortezomib/ Dexamethason .....................82 Bortezomib/ Cyclophosphamid/ Dexamethason .. .83 CD-V p.o. Standard ............................83 CD-V p.o. adaptiert............................83 CD-V i.v. ......................................84 Bortezomib/ Melphalan/ Prednison/Thalidomid .. .84 Bortezomib/ Liposomales Doxorubicin............85 Bortezomib/ Doxorubicin/ Dexamethason (BDD) ...........................................85 Bortezomib/ Lenalidomid/ Dexamethason........86 Thalidomid/ Dexamethason......................79 Thalidomid/ Prednisolon.........................80 Cyclophosphamid/Thalidomid/Dexamethason (CTD) ...........................................80 Lenalidomid/ Dexamethason.....................81 Melphalan/ Prednison (»Alexanian«)..............77 Melphalan i.v. ...................................77 Inhaltsverzeichnis Bendamustin....................................52 VAD............................................. 87 HD-Dexamethason ..............................81 HD-Dexa/ IFN alpha ..............................88 Melphalan/ Dexamethason {»Palladini-Protokoll«).. .88 Aplastische Anämien CyA/ATG/Prednisolon............................90 Paroxysmale nächtliche Hämoglobinurie Eculizumab......................................92 Teii II Solide Tumoren 8 Kopf-Hals Tumoren Doxetaxel/ Cisplatin .............................96 DCF (5d) ........................................97 Docetaxel wöchentlich...........................97 5-FU/ Cisplatin ..................................96 5-FU/ Carboplatin ...............................98 Cetuximab/ Cisplatin/ 5-FU.......................98 Cetuximab/ Carboplatin/ 5-FU....................99 Paclitaxel......................................100 EMB.............................................99 Paclitaxel/ Cisplatin/ Ifosfamid (TIP).............100 9 Thorakale Tumoren 9.1 SCLC Cisplatin/ Etoposidphosphat (limited disease)....................................... 102 Carboplatin/ Etoposidphosphat................102 EpiCo .........................................103 TEC ...........................................103 Topotecan.....................................104 Lomustin......................................104 Lomustin/ Methotrexat ........................109 9.2 NSCLC Gemcitabin/ Cisplatin..........................105 Gemcitabin/ Carboplatin.......................105 Vinorelbin/ Cisplatin (adjuvant) .................106 Vinorelbin/ Carboplatin........................106 Paclitaxel/ Carboplatin.........................107 Pemetrexed/ Cisplatin .........................107 Pemetrexed ...................................109 Paclitaxel wöchentlich/ Carboplatin ............108 Paclitaxel wöchentlich .........................100 Docetaxel .....................................108 Docetaxel wöchentlich...........................97 Gemcitabin....................................124 Vinorelbin.....................................133 Lomustin/ Methotrexat ........................109 9.3 Pleuramesotheliom Paclitaxel/ Carboplatin/Rx......................110 Gemcitabin/ Cisplatin..........................105 Pemetrexed/ Cisplatin .........................107 9.4 Thymuskarzinom PAC ...........................................111 10 Gastrointestinale Tumoren ЮЛ Ösophaguskarzinom Rx/ 5-FU/ Cisplatin (»Naunheim«)...............114 5-FU/ Carboplatin ...............................98 Cetuximab/ Cisplatin/ 5-FU.......................98 Cetuximab/ Carboplatin/ 5-FU....................99 Vinorelbin.....................................133 Docetaxel .....................................133 EOX...........................................115 10.2 Magenkarzinom DCF...........................................114 ECF ambulant .................................115 EOX...........................................115 FOLFIRI .......................................117 FLOT ..........................................116 10.3 Kolonkarzinom FOLFIRI-Bevacizumab..........................116 FOLFIRI-Cetuximab ............................117 FOLFIRI .......................................117 FOLFOX б .....................................118 FOLFOXIRI.....................................118 Xelox 2........................................119 FOLFOX 4 .....................................119 Irinotecan/ Cetuximab.........................120 Capecitabin ...................................120 5-FU/ Leukovorin ..............................121 5-FU mono (adjuvant) .........................121 Irinotecan mono...............................122 Mitomycin-C mono ............................122 Panitumumab .................................123 10.4 Analkarzinom Rx/ 5-FU/Mitomyan/ Cisplatin (»Nigro«) ........123 10.5 Pankreaskarzinom Gemcitabin....................................124 Gemcitabin/ Cisplatin..........................105 Gemcitabin/ Capecitabin.......................124 Gemcitabin/ Erlotinib..........................125 FOLFIRI .......................................117 FOLFOX б .....................................118 5-FU/Leukovorin ..............................121 10.6 Cholangiozelluläres Karzinom GemOx3 ......................................125 Capecitabin ...................................120 5-FU/ Leukovorin ..............................121 11 Gynäkologische Tumoren 11.1 Mammakarzinom FAC ...........................................129 FEC ...........................................130 AC ............................................128 EC ............................................ 128 AC+Paclitaxel (Dosisdicht).....................131 EC+ Paclitaxel .................................132 TAC ...........................................132 EP ............................................131 Gemcitabin/ Carboplatin.......................138 CMF (»ßonadonna«) ...........................134 Epirubicin .....................................129 liposomales Doxorubicin.......................130 Paclitaxel......................................100 Inhaltsverzeichnis XI Docetaxe! .....................................133 Vinorelbin.....................................133 Paclitaxel/ Trastuzumab........................134 Gemcitabin/Qsplatin/Trastuzumab............135 Trastuzumab 1x/Woche.......................137 Trastuzumab 3 - wöchentlich...................137 Paclitaxel/ Bevacizumab .......................135 Capecitabin/ Bevacizumab.....................136 Capecitabin/Lapatinib.........................136 11.2 Ovarialkarzinom Carboplatin ...................................138 Cyclophosphamid/ Carboplatin ................139 Paclitaxel......................................100 Paclitaxel/ Carboplatin.........................139 Topotecan.....................................104 Treosulfan .....................................140 Treosulfan oral ................................140 liposomales Doxorubicin .......................130 12 Urogenitaltumoren 12.1 Hodenkarzinom PEI mod (HD Studie) ...........................143 PE ............................................142 РЕВ ...........................................142 PEI............................................143 PIV+G-CSF ....................................144 Gemcitabin/ Oxaliplatin/ Paclitaxel .............144 Carboplatin mono (adjuvant) ...................145 12.2 Prostatakarzinom Doxetaxel/ Prednisolon ........................146 Cyclophosphamid/ Doxorubicin................146 Doxorubicin...................................147 Cyclophosphamid .............................145 12.3 Nierenzellkarzinom Sunitinib ......................................148 Sorafenib......................................147 HD-IL-2/ IFNa..................................148 12.4 Phäochromozytom Cyclophosphamid/Vincristin/ Dacarbazin.......149 12.5 Urothelkarzinom Gemcitabin/ Cisplatin..........................105 M-VAC ........................................149 13 Hauttumoren 13.1 Melanom CVD...........................................152 CVD/ IL2/IFNQ (»Legha«) .......................152 Legha Konsolidierung..........................153 Dacarbazin mono..............................153 Fotemustin....................................154 Lomustin......................................104 14 Sarkome 14.1 Weichteilsarkom CWS2002-P ...................................156 Doxorubicin/ Cisplatin/ Ifosfamid/ Paclitaxel......................................159 Doxorubicin/ Ifosfamid ........................160 Trabectedin ...................................160 Gemcitabin/ Docetaxel.........................161 T 4.2 Ewing-Sarkom EURO-E.W.I.N.G. 99-Studie......................161 14.3 Osteosarkom EURO-B.O-S.S.-Studie...........................165 Doxorubicin/ Ifosfamid ........................160 15 ZNS Tumoren Lomustin......................................104 Nimustin......................................170 Temozolamid..................................170 HIT2000/ NOA-07..............................171 Bevacizumab/ Irinotecan.......................171 16 Unbekannter Primärtumor PCE...........................................174 Teil III Intrakavitäre Chemotherapie Liquorinstillation »Dreierkombination« .........176 Liquorinstillation »Dreierkombination« Prophylaxe Pat. < 55J ..........................176 Liquorinstillation »Dreierkombination« Prophylaxe Pat. > 55J ..........................177 Liquorinstillation »MTX-Mono«.................177 liposomales Cytarabin .........................178 Bleomycin intraperikardial .....................178 Teil IV Mobilisierungschemotherapien VCP-E.........................................180 VIP-E..........................................180 Indi Cyclophosphamid.........................181 Cyclo-Mob-Id .................................184 СусІо-МоЬ-га .................................184 Dexa-BEAM ...................................185 IEV (<60J.).....................................181 IEV (>60J.).....................................182 EVC bei Niereninsuffizienz (<60J.) ..............182 EVC bei Niereninsuffizienz ^бОЈ.) ..............183 VC ............................................183 Teil V Autologe Konditionierungs- Protokolle PEI (mod) Arm A+B Hodencarcinom - Studie___143 CE Arm A Hodencarcinom - Studie..............195 CEC Arm В Hodencarcinom - Studie ............195 VIC ............................................194 CCT...........................................190 Busulfan/ Melphalan (EURO-E.W.I.N.G. 99).......161 Me -Ме (EURO-E.W.I.N.G. 99)....................162 BEAM + Palifermin Arm A - Studie ..............189 BEAM ohne Palifermin Arm В - Studie...........190 XII Inhaltsverzeichnis BEAM .........................................188 ВМ (>6бЈ.) .....................................191 TBI/ CYCLO Arm A MCL-Younger - Studie........189 TBI/ ARAC/ MEL Arm В MCL-Younger - Studie .... 188 Melphalan 200 DSMMXI - Studie ...............192 Melphalan140 ................................192 BCNU/Thiotepa ...............................194 Busulfan/ Cyclophosphamid ...................191 Busulfan mono p.o .............................193 Busulfan mono i.v. .............................193 Teil VI Allogene Konditionierungs- Protokolle ATG/ Flu/ Mel DSMMXI - Studie.................198 Fludarabin/ Carmustin/ Melphalan (<55J.) ......199 Fludarabin/ Carmustin/ Melphalan (>55J.) ......199 Fludarabin/ Carmustin/Thiotepa ...............201 Fludarabin/ Melphalan/Thiotepa ...............203 Fludarabin/ Busulfan ...........................201 Fludarabin/Thiotepa ...........................202 HD Cyclophosphamid/ Fludarabin ..............202 TBI/ Etoposidphosophat .......................200 TBI/ Etoposidphosophat/ Cyclophosphamid ___200 Busulfan/ Cyclophosphamid ...................198 Teil VII Supportive und andere Therapieprotokolle Amphoteridn В................................ 206 Alemtuzumab i.v. bei GvHD ....................206 Prophylaxe verzögerter Emesis moderates Risiko .........................................207 Prophylaxe verzögerter Emesis Hochrisiko......207 Romiplostim bei ITP ...........................208
any_adam_object	1
author	Engelhardt, Monika 1966- Berger, Dietmar Paul Mertelsmann, Roland 1944-
author_GND	(DE-588)113263538 (DE-588)111674808 (DE-588)122802187
author_facet	Engelhardt, Monika 1966- Berger, Dietmar Paul Mertelsmann, Roland 1944-
author_role	aut aut aut
author_sort	Engelhardt, Monika 1966-
author_variant	m e me d p b dp dpb r m rm
building	Verbundindex
bvnumber	BV036044484
classification_rvk	XH 3209
ctrlnum	(OCoLC)633726973 (DE-599)DNB998588954
dewey-full	616.994061
dewey-hundreds	600 - Technology (Applied sciences)
dewey-ones	616 - Diseases
dewey-raw	616.994061
dewey-search	616.994061
dewey-sort	3616.994061
dewey-tens	610 - Medicine and health
discipline	Medizin
edition	3. Aufl.
format	Kit Book
fullrecord	<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02733nom a2200577 c 4500</leader><controlfield tag="001">BV036044484</controlfield><controlfield tag="003">DE-604</controlfield><controlfield tag="005">20100312 </controlfield><controlfield tag="008">100222s2010 gw \|\|\| 0\| bnger d</controlfield><datafield tag="015" ind1=" " ind2=" "><subfield code="a">09,N51,1332</subfield><subfield code="2">dnb</subfield></datafield><datafield tag="016" ind1="7" ind2=" "><subfield code="a">998588954</subfield><subfield code="2">DE-101</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">9783642052941</subfield><subfield code="c">Book with CDROM. : EUR 4.95, sfr 7.50 (freier Pr.)</subfield><subfield code="9">978-3-642-05294-1</subfield></datafield><datafield tag="020" ind1=" " ind2=" "><subfield code="a">3642052940</subfield><subfield code="9">3-642-05294-0</subfield></datafield><datafield tag="024" ind1="3" ind2=" "><subfield code="a">9783642052941</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">12775231</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(OCoLC)633726973</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DNB998588954</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-604</subfield><subfield code="b">ger</subfield><subfield code="e">rakddb</subfield></datafield><datafield tag="041" ind1="0" ind2=" "><subfield code="a">ger</subfield></datafield><datafield tag="044" ind1=" " ind2=" "><subfield code="a">gw</subfield><subfield code="c">XA-DE-BE</subfield></datafield><datafield tag="049" ind1=" " ind2=" "><subfield code="a">DE-20</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">616.994061</subfield><subfield code="2">22/ger</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">XH 3209</subfield><subfield code="0">(DE-625)152888:12915</subfield><subfield code="2">rvk</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">610</subfield><subfield code="2">sdnb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Engelhardt, Monika</subfield><subfield code="d">1966-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)113263538</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Das Blaue Buch</subfield><subfield code="b">Chemotherapie-Manual Hämatologie und internistische Onkologie</subfield><subfield code="c">Monika Engelhardt ; Dietmar Berger ; Roland Mertelsmann</subfield></datafield><datafield tag="250" ind1=" " ind2=" "><subfield code="a">3. Aufl.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Berlin [u.a.]</subfield><subfield code="b">Springer</subfield><subfield code="c">2010</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">XXI, 208 S.</subfield><subfield code="b">Ill., graph. Darst.</subfield><subfield code="e">1 CD-ROM (12 cm)</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Hämatologie</subfield><subfield code="0">(DE-588)4022796-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Onkologie</subfield><subfield code="0">(DE-588)4075658-0</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="650" ind1="0" ind2="7"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="2">gnd</subfield><subfield code="9">rswk-swf</subfield></datafield><datafield tag="689" ind1="0" ind2="0"><subfield code="a">Onkologie</subfield><subfield code="0">(DE-588)4075658-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="1"><subfield code="a">Hämatologie</subfield><subfield code="0">(DE-588)4022796-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="2"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2="3"><subfield code="a">Cytostatikum</subfield><subfield code="0">(DE-588)4068347-3</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="0" ind2=" "><subfield code="8">1\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="689" ind1="1" ind2="0"><subfield code="a">Onkologie</subfield><subfield code="0">(DE-588)4075658-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="1"><subfield code="a">Hämatologie</subfield><subfield code="0">(DE-588)4022796-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="2"><subfield code="a">Chemotherapie</subfield><subfield code="0">(DE-588)4127083-6</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2="3"><subfield code="a">Krebs</subfield><subfield code="g">Medizin</subfield><subfield code="0">(DE-588)4073781-0</subfield><subfield code="D">s</subfield></datafield><datafield tag="689" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="5">DE-604</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Berger, Dietmar Paul</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)111674808</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mertelsmann, Roland</subfield><subfield code="d">1944-</subfield><subfield code="e">Verfasser</subfield><subfield code="0">(DE-588)122802187</subfield><subfield code="4">aut</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018936279&sequence=000005&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Inhaltsverzeichnis</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="m">Digitalisierung UB Regensburg</subfield><subfield code="q">application/pdf</subfield><subfield code="u">http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018936279&sequence=000006&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA</subfield><subfield code="3">Klappentext</subfield></datafield><datafield tag="999" ind1=" " ind2=" "><subfield code="a">oai:aleph.bib-bvb.de:BVB01-018936279</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">1\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield><datafield tag="883" ind1="1" ind2=" "><subfield code="8">2\p</subfield><subfield code="a">cgwrk</subfield><subfield code="d">20201028</subfield><subfield code="q">DE-101</subfield><subfield code="u">https://d-nb.info/provenance/plan#cgwrk</subfield></datafield></record></collection>
id	DE-604.BV036044484
illustrated	Illustrated
indexdate	2024-07-09T22:10:09Z
institution	BVB
isbn	9783642052941 3642052940
language	German
oai_aleph_id	oai:aleph.bib-bvb.de:BVB01-018936279
oclc_num	633726973
open_access_boolean
owner	DE-20
owner_facet	DE-20
physical	XXI, 208 S. Ill., graph. Darst. 1 CD-ROM (12 cm)
publishDate	2010
publishDateSearch	2010
publishDateSort	2010
publisher	Springer
record_format	marc
spelling	Engelhardt, Monika 1966- Verfasser (DE-588)113263538 aut Das Blaue Buch Chemotherapie-Manual Hämatologie und internistische Onkologie Monika Engelhardt ; Dietmar Berger ; Roland Mertelsmann 3. Aufl. Berlin [u.a.] Springer 2010 XXI, 208 S. Ill., graph. Darst. 1 CD-ROM (12 cm) Krebs Medizin (DE-588)4073781-0 gnd rswk-swf Hämatologie (DE-588)4022796-0 gnd rswk-swf Onkologie (DE-588)4075658-0 gnd rswk-swf Cytostatikum (DE-588)4068347-3 gnd rswk-swf Chemotherapie (DE-588)4127083-6 gnd rswk-swf Onkologie (DE-588)4075658-0 s Hämatologie (DE-588)4022796-0 s Chemotherapie (DE-588)4127083-6 s Cytostatikum (DE-588)4068347-3 s 1\p DE-604 Krebs Medizin (DE-588)4073781-0 s 2\p DE-604 Berger, Dietmar Paul Verfasser (DE-588)111674808 aut Mertelsmann, Roland 1944- Verfasser (DE-588)122802187 aut Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018936279&sequence=000005&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA Inhaltsverzeichnis Digitalisierung UB Regensburg application/pdf http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018936279&sequence=000006&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA Klappentext 1\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk 2\p cgwrk 20201028 DE-101 https://d-nb.info/provenance/plan#cgwrk
spellingShingle	Engelhardt, Monika 1966- Berger, Dietmar Paul Mertelsmann, Roland 1944- Das Blaue Buch Chemotherapie-Manual Hämatologie und internistische Onkologie Krebs Medizin (DE-588)4073781-0 gnd Hämatologie (DE-588)4022796-0 gnd Onkologie (DE-588)4075658-0 gnd Cytostatikum (DE-588)4068347-3 gnd Chemotherapie (DE-588)4127083-6 gnd
subject_GND	(DE-588)4073781-0 (DE-588)4022796-0 (DE-588)4075658-0 (DE-588)4068347-3 (DE-588)4127083-6
title	Das Blaue Buch Chemotherapie-Manual Hämatologie und internistische Onkologie
title_auth	Das Blaue Buch Chemotherapie-Manual Hämatologie und internistische Onkologie
title_exact_search	Das Blaue Buch Chemotherapie-Manual Hämatologie und internistische Onkologie
title_full	Das Blaue Buch Chemotherapie-Manual Hämatologie und internistische Onkologie Monika Engelhardt ; Dietmar Berger ; Roland Mertelsmann
title_fullStr	Das Blaue Buch Chemotherapie-Manual Hämatologie und internistische Onkologie Monika Engelhardt ; Dietmar Berger ; Roland Mertelsmann
title_full_unstemmed	Das Blaue Buch Chemotherapie-Manual Hämatologie und internistische Onkologie Monika Engelhardt ; Dietmar Berger ; Roland Mertelsmann
title_short	Das Blaue Buch
title_sort	das blaue buch chemotherapie manual hamatologie und internistische onkologie
title_sub	Chemotherapie-Manual Hämatologie und internistische Onkologie
topic	Krebs Medizin (DE-588)4073781-0 gnd Hämatologie (DE-588)4022796-0 gnd Onkologie (DE-588)4075658-0 gnd Cytostatikum (DE-588)4068347-3 gnd Chemotherapie (DE-588)4127083-6 gnd
topic_facet	Krebs Medizin Hämatologie Onkologie Cytostatikum Chemotherapie
url	http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018936279&sequence=000005&line_number=0001&func_code=DB_RECORDS&service_type=MEDIA http://bvbr.bib-bvb.de:8991/F?func=service&doc_library=BVB01&local_base=BVB01&doc_number=018936279&sequence=000006&line_number=0002&func_code=DB_RECORDS&service_type=MEDIA
work_keys_str_mv	AT engelhardtmonika dasblauebuchchemotherapiemanualhamatologieundinternistischeonkologie AT bergerdietmarpaul dasblauebuchchemotherapiemanualhamatologieundinternistischeonkologie AT mertelsmannroland dasblauebuchchemotherapiemanualhamatologieundinternistischeonkologie

Verfügbarkeit

Es ist kein Print-Exemplar vorhanden.

Fernleihe Bestellen Achtung: Nicht im THWS-Bestand! Inhaltsverzeichnis

MARC

Datensatz im Suchindex

Es ist kein Print-Exemplar vorhanden.

Ähnliche Einträge